116 related articles for article (PubMed ID: 38447779)
41. Enhanced anticancer activity and intracellular uptake of paclitaxel-containing solid lipid nanoparticles in multidrug-resistant breast cancer cells.
Xu W; Bae EJ; Lee MK
Int J Nanomedicine; 2018; 13():7549-7563. PubMed ID: 30532538
[TBL] [Abstract][Full Text] [Related]
42. Co-delivery of paclitaxel and tetrandrine via iRGD peptide conjugated lipid-polymer hybrid nanoparticles overcome multidrug resistance in cancer cells.
Zhang J; Wang L; Fai Chan H; Xie W; Chen S; He C; Wang Y; Chen M
Sci Rep; 2017 May; 7():46057. PubMed ID: 28470171
[TBL] [Abstract][Full Text] [Related]
43. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells.
Yadav S; van Vlerken LE; Little SR; Amiji MM
Cancer Chemother Pharmacol; 2009 Mar; 63(4):711-22. PubMed ID: 18618115
[TBL] [Abstract][Full Text] [Related]
44. Systematic evaluation of multifunctional paclitaxel-loaded polymeric mixed micelles as a potential anticancer remedy to overcome multidrug resistance.
Zhang J; Zhao X; Chen Q; Yin X; Xin X; Li K; Qiao M; Hu H; Chen D; Zhao X
Acta Biomater; 2017 Mar; 50():381-395. PubMed ID: 27956367
[TBL] [Abstract][Full Text] [Related]
45. tLyP-1 Peptide Functionalized Human H Chain Ferritin for Targeted Delivery of Paclitaxel.
Ma Y; Li R; Dong Y; You C; Huang S; Li X; Wang F; Zhang Y
Int J Nanomedicine; 2021; 16():789-802. PubMed ID: 33568906
[TBL] [Abstract][Full Text] [Related]
46. A light-controllable specific drug delivery nanoplatform for targeted bimodal imaging-guided photothermal/chemo synergistic cancer therapy.
Guo Y; Wang XY; Chen YL; Liu FQ; Tan MX; Ao M; Yu JH; Ran HT; Wang ZX
Acta Biomater; 2018 Oct; 80():308-326. PubMed ID: 30240955
[TBL] [Abstract][Full Text] [Related]
47. Dual-functionalized liposome by co-delivery of paclitaxel with sorafenib for synergistic antitumor efficacy and reversion of multidrug resistance.
Lei M; Ma G; Sha S; Wang X; Feng H; Zhu Y; Du X
Drug Deliv; 2019 Dec; 26(1):262-272. PubMed ID: 30856352
[TBL] [Abstract][Full Text] [Related]
48. Co-delivery of paclitaxel and curcumin by biodegradable polymeric nanoparticles for breast cancer chemotherapy.
Xiong K; Zhang Y; Wen Q; Luo J; Lu Y; Wu Z; Wang B; Chen Y; Zhao L; Fu S
Int J Pharm; 2020 Nov; 589():119875. PubMed ID: 32919003
[TBL] [Abstract][Full Text] [Related]
49. Preparation and Characterization of Albumin Nanoparticles of Paclitaxel-Triphenylphosphonium Conjugates: New Approach to Subcellular Targeting.
Hosseinifar N; Goodarzi N; Sharif AAM; Amini M; Esfandyari-Manesh M; Dinarvand R
Drug Res (Stuttg); 2020 Feb; 70(2-03):71-79. PubMed ID: 31986546
[TBL] [Abstract][Full Text] [Related]
50. PAMAM G4.5 dendrimers for targeted delivery of ferulic acid and paclitaxel to overcome P-glycoprotein-mediated multidrug resistance.
Anbazhagan R; Muthusamy G; Krishnamoorthi R; Kumaresan S; Rajendra Prasad N; Lai JY; Yang JM; Tsai HC
Biotechnol Bioeng; 2021 Mar; 118(3):1213-1223. PubMed ID: 33289076
[TBL] [Abstract][Full Text] [Related]
51. Redox-sensitive carrier-free nanoparticles self-assembled by disulfide-linked paclitaxel-tetramethylpyrazine conjugate for combination cancer chemotherapy.
Zou L; Liu X; Li J; Li W; Zhang L; Fu C; Zhang J; Gu Z
Theranostics; 2021; 11(9):4171-4186. PubMed ID: 33754055
[No Abstract] [Full Text] [Related]
52. Redox-sensitive mPEG-SS-PTX/TPGS mixed micelles: An efficient drug delivery system for overcoming multidrug resistance.
Zhao D; Zhang H; Yang S; He W; Luan Y
Int J Pharm; 2016 Dec; 515(1-2):281-292. PubMed ID: 27746331
[TBL] [Abstract][Full Text] [Related]
53. Paclitaxel-loaded N-octyl-O-sulfate chitosan micelles for superior cancer therapeutic efficacy and overcoming drug resistance.
Jin X; Mo R; Ding Y; Zheng W; Zhang C
Mol Pharm; 2014 Jan; 11(1):145-57. PubMed ID: 24261922
[TBL] [Abstract][Full Text] [Related]
54. Target delivering paclitaxel by ferritin heavy chain nanocages for glioma treatment.
Liu W; Lin Q; Fu Y; Huang S; Guo C; Li L; Wang L; Zhang Z; Zhang L
J Control Release; 2020 Jul; 323():191-202. PubMed ID: 31838201
[TBL] [Abstract][Full Text] [Related]
55. Enhanced anticancer efficacy of paclitaxel through multistage tumor-targeting liposomes modified with RGD and KLA peptides.
Sun J; Jiang L; Lin Y; Gerhard EM; Jiang X; Li L; Yang J; Gu Z
Int J Nanomedicine; 2017; 12():1517-1537. PubMed ID: 28280323
[TBL] [Abstract][Full Text] [Related]
56. l-Peptide functionalized dual-responsive nanoparticles for controlled paclitaxel release and enhanced apoptosis in breast cancer cells.
Niu S; Bremner DH; Wu J; Wu J; Wang H; Li H; Qian Q; Zheng H; Zhu L
Drug Deliv; 2018 Nov; 25(1):1275-1288. PubMed ID: 29847177
[TBL] [Abstract][Full Text] [Related]
57. Enhanced drug-loading and therapeutic efficacy of hydrotropic oligomer-conjugated glycol chitosan nanoparticles for tumor-targeted paclitaxel delivery.
Koo H; Min KH; Lee SC; Park JH; Park K; Jeong SY; Choi K; Kwon IC; Kim K
J Control Release; 2013 Dec; 172(3):823-31. PubMed ID: 24035978
[TBL] [Abstract][Full Text] [Related]
58. Therapeutic strategies to overcome taxane resistance in cancer.
Das T; Anand U; Pandey SK; Ashby CR; Assaraf YG; Chen ZS; Dey A
Drug Resist Updat; 2021 Mar; 55():100754. PubMed ID: 33691261
[TBL] [Abstract][Full Text] [Related]
59. Hyaluronic Acid-Targeted Stimuli-Sensitive Nanomicelles Co-Encapsulating Paclitaxel and Ritonavir to Overcome Multi-Drug Resistance in Metastatic Breast Cancer and Triple-Negative Breast Cancer Cells.
Gote V; Sharma AD; Pal D
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513992
[TBL] [Abstract][Full Text] [Related]
60. Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes.
Jin M; Jin G; Kang L; Chen L; Gao Z; Huang W
Int J Nanomedicine; 2018; 13():2405-2426. PubMed ID: 29719390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
